Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics, Inc. - Common Stock (NQ:VRDN)

22.77 -0.31 (-1.34%)
Streaming Delayed Price Updated: 10:59 AM EDT, Aug 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Viridian Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Prepares for Transformational 2026
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Proposed Underwritten Public Offering
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
From Viridian Therapeutics, Inc.
Via Business Wire
News headline image
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.